| 摘要 |
A modification of a human ciliary neurotrophic factor (human CNTF) wherein the amino acid residue of the amino acid sequence corresponding to at least the 153rd amino acid residue of the amino acid sequence of a natural human CNTF has been replaced by another amino acid residue has an activity equal or superior to that of a natural human CNTF. Hence it is expected as a useful therapeuticc agent reduced in the side effects such as the occurrence of autoantibodies caused by ample administration thereof, body weight decrease, anorexia, dry cough, and boredom. The invention also provides a D1 cap region modification of alpha -helix-rich cytokines analogous to human CNTF, such as GH, PRL, EPC, G-CSF, LIF, IL-6, IL-2, IL-4, and GM-CSF. <IMAGE> |
